This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.
Learn more about the activities of EPCCS that are aimed at supporting primary care professionals manage their patients with cardiovascular and cardiometabolic disease.
High number of ideal CV health metrics is associated with low incidence of diabetes in subjects with normal fasting glucose, but not in those with impaired fasting glucose.
Use of aspirin resulted in reduction of composite of CV mortality, nonfatal MI and nonfatal stroke in primary prevention setting, shown in a meta-analysis including 13 trials with more than 164.000 individuals, but at the cost of higher risk of major bleeding.
The Diabetes Lifetime-perspective prediction (DIAL) model was developed and can be used in the U-Prevent decision tool to predict individual CVD-free life expectancy and the effect of lifelong treatment on CVD-free life-years gained.
EAPC Position Statement states that exercise programs for diabetics are a cost effective treatment and should be reimbursed
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
AHA 2018 Dapagliflozin was evaluated in both primary and secondary prevention patients with T2DM. Stephen Wiviott summarizes the results of DECLARE TIMI-58, along with those of a meta-analysis of the 3 SGLT2i CVOTs.
Structural brain abnormalities are more common in patients with prediabetes compared with non-diabetics, and even more common in T2DM patients.
AHA 2018 Dapagliflozin was associated with a reduction in CVD/hospitalization in T2DM patients with ASCVD or with multiple risk factors, and with a modest decrease in MACE in those with existing ASCVD.
AHA 2018 The American Heart Association (AHA) and the American College of Cardiology (ACC) updated the 2018 cholesterol guidelines. A summary of key recommendations concerning cholesterol management in de prevention of CVD.
In this randomized trial, the long-term intensive PREDIMED-Plus lifestyle intervention resulted in weight loss and reduced CV risk in overweight/obese adults with metabolic syndrome, compared to standard care.